nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—UGT2B7—urinary bladder cancer	0.414	1	CbGaD
Valproic Acid—UGT2B7—Epirubicin—urinary bladder cancer	0.0368	0.13	CbGbCtD
Valproic Acid—CYP2B6—Thiotepa—urinary bladder cancer	0.0354	0.125	CbGbCtD
Valproic Acid—SLC16A1—Methotrexate—urinary bladder cancer	0.0349	0.123	CbGbCtD
Valproic Acid—SLC22A7—Fluorouracil—urinary bladder cancer	0.0311	0.11	CbGbCtD
Valproic Acid—CYP2A6—Fluorouracil—urinary bladder cancer	0.0177	0.0625	CbGbCtD
Valproic Acid—SLC22A7—Methotrexate—urinary bladder cancer	0.0171	0.0607	CbGbCtD
Valproic Acid—PTGS1—Etoposide—urinary bladder cancer	0.0126	0.0446	CbGbCtD
Valproic Acid—CYP3A4—Thiotepa—urinary bladder cancer	0.0109	0.0385	CbGbCtD
Valproic Acid—SLC22A8—Methotrexate—urinary bladder cancer	0.0105	0.0371	CbGbCtD
Valproic Acid—CYP2B6—Cisplatin—urinary bladder cancer	0.00976	0.0345	CbGbCtD
Valproic Acid—CYP2C8—Fluorouracil—urinary bladder cancer	0.0087	0.0308	CbGbCtD
Valproic Acid—CYP3A5—Etoposide—urinary bladder cancer	0.00756	0.0267	CbGbCtD
Valproic Acid—SLC22A6—Methotrexate—urinary bladder cancer	0.00729	0.0258	CbGbCtD
Valproic Acid—CYP2C8—Etoposide—urinary bladder cancer	0.00726	0.0257	CbGbCtD
Valproic Acid—CYP1A2—Fluorouracil—urinary bladder cancer	0.00674	0.0238	CbGbCtD
Valproic Acid—CYP2B6—Doxorubicin—urinary bladder cancer	0.00654	0.0232	CbGbCtD
Valproic Acid—CYP2C9—Fluorouracil—urinary bladder cancer	0.00607	0.0215	CbGbCtD
Valproic Acid—CYP1A2—Etoposide—urinary bladder cancer	0.00562	0.0199	CbGbCtD
Valproic Acid—OGDH—urine—urinary bladder cancer	0.00526	0.0813	CbGeAlD
Valproic Acid—CYP2C9—Cisplatin—urinary bladder cancer	0.00516	0.0183	CbGbCtD
Valproic Acid—CYP3A4—Etoposide—urinary bladder cancer	0.00295	0.0104	CbGbCtD
Valproic Acid—UGT1A6—prostate gland—urinary bladder cancer	0.00239	0.0369	CbGeAlD
Valproic Acid—CYP3A4—Doxorubicin—urinary bladder cancer	0.00201	0.00711	CbGbCtD
Valproic Acid—OGDH—prostate gland—urinary bladder cancer	0.00189	0.0292	CbGeAlD
Valproic Acid—UGT1A10—renal system—urinary bladder cancer	0.00175	0.0271	CbGeAlD
Valproic Acid—UGT2B15—prostate gland—urinary bladder cancer	0.0017	0.0263	CbGeAlD
Valproic Acid—HDAC9—prostate gland—urinary bladder cancer	0.00167	0.0257	CbGeAlD
Valproic Acid—SLC22A8—urine—urinary bladder cancer	0.00159	0.0246	CbGeAlD
Valproic Acid—ACADSB—prostate gland—urinary bladder cancer	0.0015	0.0232	CbGeAlD
Valproic Acid—UGT1A8—renal system—urinary bladder cancer	0.00138	0.0214	CbGeAlD
Valproic Acid—CYP2C19—urine—urinary bladder cancer	0.00134	0.0206	CbGeAlD
Valproic Acid—ALDH5A1—prostate gland—urinary bladder cancer	0.00132	0.0204	CbGeAlD
Valproic Acid—OGDH—renal system—urinary bladder cancer	0.00129	0.0199	CbGeAlD
Valproic Acid—ACADSB—seminal vesicle—urinary bladder cancer	0.00127	0.0196	CbGeAlD
Valproic Acid—OGDH—urethra—urinary bladder cancer	0.00126	0.0195	CbGeAlD
Valproic Acid—HDAC2—Teniposide—Etoposide—urinary bladder cancer	0.00115	1	CbGdCrCtD
Valproic Acid—UGT2B15—urethra—urinary bladder cancer	0.00114	0.0176	CbGeAlD
Valproic Acid—ABAT—prostate gland—urinary bladder cancer	0.00113	0.0175	CbGeAlD
Valproic Acid—CYP1A2—urine—urinary bladder cancer	0.00109	0.0168	CbGeAlD
Valproic Acid—UGT1A4—renal system—urinary bladder cancer	0.00105	0.0162	CbGeAlD
Valproic Acid—UGT2B7—prostate gland—urinary bladder cancer	0.00104	0.0161	CbGeAlD
Valproic Acid—CYP2C9—urine—urinary bladder cancer	0.00104	0.016	CbGeAlD
Valproic Acid—OGDH—female reproductive system—urinary bladder cancer	0.00103	0.0159	CbGeAlD
Valproic Acid—ACADSB—renal system—urinary bladder cancer	0.00102	0.0158	CbGeAlD
Valproic Acid—ACADSB—urethra—urinary bladder cancer	0.001	0.0155	CbGeAlD
Valproic Acid—UGT2B15—female reproductive system—urinary bladder cancer	0.000929	0.0144	CbGeAlD
Valproic Acid—HDAC9—female reproductive system—urinary bladder cancer	0.000909	0.014	CbGeAlD
Valproic Acid—ALDH5A1—renal system—urinary bladder cancer	0.0009	0.0139	CbGeAlD
Valproic Acid—UGT1A9—renal system—urinary bladder cancer	0.000879	0.0136	CbGeAlD
Valproic Acid—HDAC2—prostate gland—urinary bladder cancer	0.000851	0.0131	CbGeAlD
Valproic Acid—ACADSB—female reproductive system—urinary bladder cancer	0.000819	0.0126	CbGeAlD
Valproic Acid—CYP3A4—urine—urinary bladder cancer	0.00079	0.0122	CbGeAlD
Valproic Acid—ABAT—renal system—urinary bladder cancer	0.00077	0.0119	CbGeAlD
Valproic Acid—SLC16A1—prostate gland—urinary bladder cancer	0.000756	0.0117	CbGeAlD
Valproic Acid—CYP2A6—prostate gland—urinary bladder cancer	0.000745	0.0115	CbGeAlD
Valproic Acid—ACADSB—vagina—urinary bladder cancer	0.000741	0.0114	CbGeAlD
Valproic Acid—ALDH5A1—female reproductive system—urinary bladder cancer	0.000721	0.0111	CbGeAlD
Valproic Acid—UGT2B7—renal system—urinary bladder cancer	0.000709	0.0109	CbGeAlD
Valproic Acid—SLC22A7—renal system—urinary bladder cancer	0.000674	0.0104	CbGeAlD
Valproic Acid—ALDH5A1—vagina—urinary bladder cancer	0.000652	0.0101	CbGeAlD
Valproic Acid—CYP2A6—seminal vesicle—urinary bladder cancer	0.00063	0.00974	CbGeAlD
Valproic Acid—HDAC2—epithelium—urinary bladder cancer	0.000626	0.00966	CbGeAlD
Valproic Acid—OGDH—lymph node—urinary bladder cancer	0.000603	0.00931	CbGeAlD
Valproic Acid—HDAC2—smooth muscle tissue—urinary bladder cancer	0.000603	0.00931	CbGeAlD
Valproic Acid—HDAC2—renal system—urinary bladder cancer	0.00058	0.00896	CbGeAlD
Valproic Acid—SLC22A8—prostate gland—urinary bladder cancer	0.000572	0.00883	CbGeAlD
Valproic Acid—UGT2B7—female reproductive system—urinary bladder cancer	0.000568	0.00877	CbGeAlD
Valproic Acid—ABAT—vagina—urinary bladder cancer	0.000558	0.00862	CbGeAlD
Valproic Acid—CYP2C18—vagina—urinary bladder cancer	0.000557	0.0086	CbGeAlD
Valproic Acid—SLC16A1—epithelium—urinary bladder cancer	0.000556	0.00858	CbGeAlD
Valproic Acid—HDAC9—lymph node—urinary bladder cancer	0.000532	0.00821	CbGeAlD
Valproic Acid—SLC16A1—renal system—urinary bladder cancer	0.000516	0.00796	CbGeAlD
Valproic Acid—ACADSB—lymph node—urinary bladder cancer	0.000479	0.0074	CbGeAlD
Valproic Acid—HDAC2—female reproductive system—urinary bladder cancer	0.000465	0.00718	CbGeAlD
Valproic Acid—SLC22A5—prostate gland—urinary bladder cancer	0.000432	0.00667	CbGeAlD
Valproic Acid—ALDH5A1—lymph node—urinary bladder cancer	0.000422	0.00651	CbGeAlD
Valproic Acid—HDAC2—vagina—urinary bladder cancer	0.00042	0.00649	CbGeAlD
Valproic Acid—SLC16A1—female reproductive system—urinary bladder cancer	0.000413	0.00638	CbGeAlD
Valproic Acid—SLC22A8—renal system—urinary bladder cancer	0.00039	0.00602	CbGeAlD
Valproic Acid—CYP3A5—prostate gland—urinary bladder cancer	0.000378	0.00583	CbGeAlD
Valproic Acid—CYP2A6—vagina—urinary bladder cancer	0.000368	0.00568	CbGeAlD
Valproic Acid—SLC22A5—seminal vesicle—urinary bladder cancer	0.000366	0.00565	CbGeAlD
Valproic Acid—ABAT—lymph node—urinary bladder cancer	0.000361	0.00557	CbGeAlD
Valproic Acid—PTGS1—prostate gland—urinary bladder cancer	0.000339	0.00524	CbGeAlD
Valproic Acid—SLC22A5—renal system—urinary bladder cancer	0.000295	0.00455	CbGeAlD
Valproic Acid—SLC22A5—urethra—urinary bladder cancer	0.000289	0.00447	CbGeAlD
Valproic Acid—PTGS1—seminal vesicle—urinary bladder cancer	0.000287	0.00443	CbGeAlD
Valproic Acid—CYP2C8—renal system—urinary bladder cancer	0.000285	0.0044	CbGeAlD
Valproic Acid—HDAC2—lymph node—urinary bladder cancer	0.000272	0.0042	CbGeAlD
Valproic Acid—CYP1A2—renal system—urinary bladder cancer	0.000267	0.00412	CbGeAlD
Valproic Acid—CYP3A5—renal system—urinary bladder cancer	0.000257	0.00397	CbGeAlD
Valproic Acid—CYP2B6—renal system—urinary bladder cancer	0.000256	0.00395	CbGeAlD
Valproic Acid—PTGS1—epithelium—urinary bladder cancer	0.000249	0.00385	CbGeAlD
Valproic Acid—SLC16A1—lymph node—urinary bladder cancer	0.000242	0.00373	CbGeAlD
Valproic Acid—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00024	0.00371	CbGeAlD
Valproic Acid—CYP2C19—vagina—urinary bladder cancer	0.000237	0.00365	CbGeAlD
Valproic Acid—SLC22A5—female reproductive system—urinary bladder cancer	0.000236	0.00364	CbGeAlD
Valproic Acid—PTGS1—renal system—urinary bladder cancer	0.000231	0.00357	CbGeAlD
Valproic Acid—CYP2C8—female reproductive system—urinary bladder cancer	0.000228	0.00353	CbGeAlD
Valproic Acid—SLC22A5—vagina—urinary bladder cancer	0.000213	0.0033	CbGeAlD
Valproic Acid—CYP2C8—vagina—urinary bladder cancer	0.000207	0.00319	CbGeAlD
Valproic Acid—CYP2B6—female reproductive system—urinary bladder cancer	0.000205	0.00316	CbGeAlD
Valproic Acid—CYP2C9—female reproductive system—urinary bladder cancer	0.000203	0.00313	CbGeAlD
Valproic Acid—CYP3A4—renal system—urinary bladder cancer	0.000193	0.00298	CbGeAlD
Valproic Acid—CYP3A5—vagina—urinary bladder cancer	0.000186	0.00288	CbGeAlD
Valproic Acid—CYP2B6—vagina—urinary bladder cancer	0.000185	0.00286	CbGeAlD
Valproic Acid—PTGS1—female reproductive system—urinary bladder cancer	0.000185	0.00286	CbGeAlD
Valproic Acid—PTGS1—vagina—urinary bladder cancer	0.000168	0.00259	CbGeAlD
Valproic Acid—CYP3A4—female reproductive system—urinary bladder cancer	0.000155	0.00239	CbGeAlD
Valproic Acid—SLC22A5—lymph node—urinary bladder cancer	0.000138	0.00213	CbGeAlD
Valproic Acid—PTGS1—lymph node—urinary bladder cancer	0.000108	0.00167	CbGeAlD
Valproic Acid—Eye disorder—Methotrexate—urinary bladder cancer	5.22e-05	0.000447	CcSEcCtD
Valproic Acid—Diarrhoea—Fluorouracil—urinary bladder cancer	5.22e-05	0.000447	CcSEcCtD
Valproic Acid—Tinnitus—Methotrexate—urinary bladder cancer	5.2e-05	0.000446	CcSEcCtD
Valproic Acid—Hypoaesthesia—Epirubicin—urinary bladder cancer	5.2e-05	0.000446	CcSEcCtD
Valproic Acid—Asthenia—Cisplatin—urinary bladder cancer	5.18e-05	0.000445	CcSEcCtD
Valproic Acid—Pharyngitis—Epirubicin—urinary bladder cancer	5.18e-05	0.000445	CcSEcCtD
Valproic Acid—Sweating—Doxorubicin—urinary bladder cancer	5.16e-05	0.000443	CcSEcCtD
Valproic Acid—Urinary tract disorder—Epirubicin—urinary bladder cancer	5.16e-05	0.000442	CcSEcCtD
Valproic Acid—Oedema peripheral—Epirubicin—urinary bladder cancer	5.15e-05	0.000441	CcSEcCtD
Valproic Acid—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.13e-05	0.00044	CcSEcCtD
Valproic Acid—Urethral disorder—Epirubicin—urinary bladder cancer	5.12e-05	0.000439	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.09e-05	0.000437	CcSEcCtD
Valproic Acid—Epistaxis—Doxorubicin—urinary bladder cancer	5.08e-05	0.000436	CcSEcCtD
Valproic Acid—Angiopathy—Methotrexate—urinary bladder cancer	5.06e-05	0.000434	CcSEcCtD
Valproic Acid—Sinusitis—Doxorubicin—urinary bladder cancer	5.05e-05	0.000433	CcSEcCtD
Valproic Acid—Immune system disorder—Methotrexate—urinary bladder cancer	5.04e-05	0.000432	CcSEcCtD
Valproic Acid—Dizziness—Fluorouracil—urinary bladder cancer	5.04e-05	0.000432	CcSEcCtD
Valproic Acid—Visual impairment—Epirubicin—urinary bladder cancer	5.03e-05	0.000432	CcSEcCtD
Valproic Acid—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.03e-05	0.000431	CcSEcCtD
Valproic Acid—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.02e-05	0.000431	CcSEcCtD
Valproic Acid—Chills—Methotrexate—urinary bladder cancer	5.01e-05	0.00043	CcSEcCtD
Valproic Acid—Diarrhoea—Cisplatin—urinary bladder cancer	4.94e-05	0.000424	CcSEcCtD
Valproic Acid—Erythema multiforme—Epirubicin—urinary bladder cancer	4.94e-05	0.000424	CcSEcCtD
Valproic Acid—Alopecia—Methotrexate—urinary bladder cancer	4.93e-05	0.000423	CcSEcCtD
Valproic Acid—Vomiting—Gemcitabine—urinary bladder cancer	4.93e-05	0.000423	CcSEcCtD
Valproic Acid—Bradycardia—Doxorubicin—urinary bladder cancer	4.92e-05	0.000422	CcSEcCtD
Valproic Acid—Mental disorder—Methotrexate—urinary bladder cancer	4.89e-05	0.000419	CcSEcCtD
Valproic Acid—Rash—Gemcitabine—urinary bladder cancer	4.89e-05	0.000419	CcSEcCtD
Valproic Acid—Dermatitis—Gemcitabine—urinary bladder cancer	4.88e-05	0.000419	CcSEcCtD
Valproic Acid—Eye disorder—Epirubicin—urinary bladder cancer	4.88e-05	0.000419	CcSEcCtD
Valproic Acid—Hypersensitivity—Etoposide—urinary bladder cancer	4.88e-05	0.000418	CcSEcCtD
Valproic Acid—Tinnitus—Epirubicin—urinary bladder cancer	4.87e-05	0.000418	CcSEcCtD
Valproic Acid—Malnutrition—Methotrexate—urinary bladder cancer	4.86e-05	0.000417	CcSEcCtD
Valproic Acid—Haemoglobin—Doxorubicin—urinary bladder cancer	4.86e-05	0.000417	CcSEcCtD
Valproic Acid—Headache—Gemcitabine—urinary bladder cancer	4.86e-05	0.000417	CcSEcCtD
Valproic Acid—Vomiting—Fluorouracil—urinary bladder cancer	4.85e-05	0.000416	CcSEcCtD
Valproic Acid—Rhinitis—Doxorubicin—urinary bladder cancer	4.85e-05	0.000416	CcSEcCtD
Valproic Acid—Haemorrhage—Doxorubicin—urinary bladder cancer	4.83e-05	0.000415	CcSEcCtD
Valproic Acid—Hypoaesthesia—Doxorubicin—urinary bladder cancer	4.81e-05	0.000412	CcSEcCtD
Valproic Acid—Rash—Fluorouracil—urinary bladder cancer	4.81e-05	0.000412	CcSEcCtD
Valproic Acid—Dermatitis—Fluorouracil—urinary bladder cancer	4.8e-05	0.000412	CcSEcCtD
Valproic Acid—Pharyngitis—Doxorubicin—urinary bladder cancer	4.8e-05	0.000411	CcSEcCtD
Valproic Acid—Headache—Fluorouracil—urinary bladder cancer	4.78e-05	0.00041	CcSEcCtD
Valproic Acid—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.77e-05	0.000409	CcSEcCtD
Valproic Acid—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.76e-05	0.000408	CcSEcCtD
Valproic Acid—Dysgeusia—Methotrexate—urinary bladder cancer	4.76e-05	0.000408	CcSEcCtD
Valproic Acid—Asthenia—Etoposide—urinary bladder cancer	4.75e-05	0.000407	CcSEcCtD
Valproic Acid—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.75e-05	0.000407	CcSEcCtD
Valproic Acid—Angiopathy—Epirubicin—urinary bladder cancer	4.74e-05	0.000406	CcSEcCtD
Valproic Acid—Urethral disorder—Doxorubicin—urinary bladder cancer	4.74e-05	0.000406	CcSEcCtD
Valproic Acid—Immune system disorder—Epirubicin—urinary bladder cancer	4.72e-05	0.000405	CcSEcCtD
Valproic Acid—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.71e-05	0.000404	CcSEcCtD
Valproic Acid—Back pain—Methotrexate—urinary bladder cancer	4.7e-05	0.000403	CcSEcCtD
Valproic Acid—Chills—Epirubicin—urinary bladder cancer	4.69e-05	0.000402	CcSEcCtD
Valproic Acid—Pruritus—Etoposide—urinary bladder cancer	4.68e-05	0.000402	CcSEcCtD
Valproic Acid—Arrhythmia—Epirubicin—urinary bladder cancer	4.67e-05	0.0004	CcSEcCtD
Valproic Acid—Visual impairment—Doxorubicin—urinary bladder cancer	4.66e-05	0.0004	CcSEcCtD
Valproic Acid—Alopecia—Epirubicin—urinary bladder cancer	4.62e-05	0.000396	CcSEcCtD
Valproic Acid—Nausea—Gemcitabine—urinary bladder cancer	4.61e-05	0.000395	CcSEcCtD
Valproic Acid—Vomiting—Cisplatin—urinary bladder cancer	4.59e-05	0.000394	CcSEcCtD
Valproic Acid—Vision blurred—Methotrexate—urinary bladder cancer	4.58e-05	0.000393	CcSEcCtD
Valproic Acid—Mental disorder—Epirubicin—urinary bladder cancer	4.58e-05	0.000393	CcSEcCtD
Valproic Acid—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.57e-05	0.000392	CcSEcCtD
Valproic Acid—Rash—Cisplatin—urinary bladder cancer	4.56e-05	0.000391	CcSEcCtD
Valproic Acid—Dermatitis—Cisplatin—urinary bladder cancer	4.55e-05	0.00039	CcSEcCtD
Valproic Acid—Malnutrition—Epirubicin—urinary bladder cancer	4.55e-05	0.00039	CcSEcCtD
Valproic Acid—Diarrhoea—Etoposide—urinary bladder cancer	4.53e-05	0.000389	CcSEcCtD
Valproic Acid—Nausea—Fluorouracil—urinary bladder cancer	4.53e-05	0.000388	CcSEcCtD
Valproic Acid—Eye disorder—Doxorubicin—urinary bladder cancer	4.52e-05	0.000387	CcSEcCtD
Valproic Acid—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.51e-05	0.000387	CcSEcCtD
Valproic Acid—Tinnitus—Doxorubicin—urinary bladder cancer	4.51e-05	0.000387	CcSEcCtD
Valproic Acid—Anaemia—Methotrexate—urinary bladder cancer	4.49e-05	0.000385	CcSEcCtD
Valproic Acid—Flatulence—Epirubicin—urinary bladder cancer	4.48e-05	0.000384	CcSEcCtD
Valproic Acid—Tension—Epirubicin—urinary bladder cancer	4.46e-05	0.000383	CcSEcCtD
Valproic Acid—Dysgeusia—Epirubicin—urinary bladder cancer	4.45e-05	0.000382	CcSEcCtD
Valproic Acid—Nervousness—Epirubicin—urinary bladder cancer	4.42e-05	0.000379	CcSEcCtD
Valproic Acid—Back pain—Epirubicin—urinary bladder cancer	4.4e-05	0.000377	CcSEcCtD
Valproic Acid—Angiopathy—Doxorubicin—urinary bladder cancer	4.38e-05	0.000376	CcSEcCtD
Valproic Acid—Malaise—Methotrexate—urinary bladder cancer	4.38e-05	0.000376	CcSEcCtD
Valproic Acid—Dizziness—Etoposide—urinary bladder cancer	4.38e-05	0.000376	CcSEcCtD
Valproic Acid—Muscle spasms—Epirubicin—urinary bladder cancer	4.37e-05	0.000375	CcSEcCtD
Valproic Acid—Immune system disorder—Doxorubicin—urinary bladder cancer	4.37e-05	0.000374	CcSEcCtD
Valproic Acid—Vertigo—Methotrexate—urinary bladder cancer	4.37e-05	0.000374	CcSEcCtD
Valproic Acid—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.36e-05	0.000374	CcSEcCtD
Valproic Acid—Leukopenia—Methotrexate—urinary bladder cancer	4.35e-05	0.000373	CcSEcCtD
Valproic Acid—Chills—Doxorubicin—urinary bladder cancer	4.34e-05	0.000372	CcSEcCtD
Valproic Acid—Arrhythmia—Doxorubicin—urinary bladder cancer	4.32e-05	0.00037	CcSEcCtD
Valproic Acid—Nausea—Cisplatin—urinary bladder cancer	4.29e-05	0.000368	CcSEcCtD
Valproic Acid—Vision blurred—Epirubicin—urinary bladder cancer	4.29e-05	0.000368	CcSEcCtD
Valproic Acid—Alopecia—Doxorubicin—urinary bladder cancer	4.27e-05	0.000366	CcSEcCtD
Valproic Acid—Cough—Methotrexate—urinary bladder cancer	4.24e-05	0.000364	CcSEcCtD
Valproic Acid—Mental disorder—Doxorubicin—urinary bladder cancer	4.23e-05	0.000363	CcSEcCtD
Valproic Acid—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.22e-05	0.000362	CcSEcCtD
Valproic Acid—Vomiting—Etoposide—urinary bladder cancer	4.21e-05	0.000361	CcSEcCtD
Valproic Acid—Malnutrition—Doxorubicin—urinary bladder cancer	4.21e-05	0.000361	CcSEcCtD
Valproic Acid—Anaemia—Epirubicin—urinary bladder cancer	4.2e-05	0.00036	CcSEcCtD
Valproic Acid—Agitation—Epirubicin—urinary bladder cancer	4.18e-05	0.000358	CcSEcCtD
Valproic Acid—Rash—Etoposide—urinary bladder cancer	4.17e-05	0.000358	CcSEcCtD
Valproic Acid—Dermatitis—Etoposide—urinary bladder cancer	4.17e-05	0.000358	CcSEcCtD
Valproic Acid—Headache—Etoposide—urinary bladder cancer	4.15e-05	0.000356	CcSEcCtD
Valproic Acid—Flatulence—Doxorubicin—urinary bladder cancer	4.15e-05	0.000356	CcSEcCtD
Valproic Acid—Arthralgia—Methotrexate—urinary bladder cancer	4.14e-05	0.000355	CcSEcCtD
Valproic Acid—Chest pain—Methotrexate—urinary bladder cancer	4.14e-05	0.000355	CcSEcCtD
Valproic Acid—Myalgia—Methotrexate—urinary bladder cancer	4.14e-05	0.000355	CcSEcCtD
Valproic Acid—Tension—Doxorubicin—urinary bladder cancer	4.13e-05	0.000354	CcSEcCtD
Valproic Acid—Dysgeusia—Doxorubicin—urinary bladder cancer	4.12e-05	0.000353	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.11e-05	0.000352	CcSEcCtD
Valproic Acid—Malaise—Epirubicin—urinary bladder cancer	4.1e-05	0.000352	CcSEcCtD
Valproic Acid—Discomfort—Methotrexate—urinary bladder cancer	4.09e-05	0.000351	CcSEcCtD
Valproic Acid—Nervousness—Doxorubicin—urinary bladder cancer	4.09e-05	0.000351	CcSEcCtD
Valproic Acid—Vertigo—Epirubicin—urinary bladder cancer	4.09e-05	0.00035	CcSEcCtD
Valproic Acid—Leukopenia—Epirubicin—urinary bladder cancer	4.07e-05	0.000349	CcSEcCtD
Valproic Acid—Back pain—Doxorubicin—urinary bladder cancer	4.07e-05	0.000349	CcSEcCtD
Valproic Acid—Muscle spasms—Doxorubicin—urinary bladder cancer	4.04e-05	0.000347	CcSEcCtD
Valproic Acid—Palpitations—Epirubicin—urinary bladder cancer	4.02e-05	0.000345	CcSEcCtD
Valproic Acid—Confusional state—Methotrexate—urinary bladder cancer	4e-05	0.000343	CcSEcCtD
Valproic Acid—Cough—Epirubicin—urinary bladder cancer	3.97e-05	0.00034	CcSEcCtD
Valproic Acid—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.97e-05	0.00034	CcSEcCtD
Valproic Acid—Vision blurred—Doxorubicin—urinary bladder cancer	3.97e-05	0.00034	CcSEcCtD
Valproic Acid—Infection—Methotrexate—urinary bladder cancer	3.94e-05	0.000338	CcSEcCtD
Valproic Acid—Nausea—Etoposide—urinary bladder cancer	3.93e-05	0.000337	CcSEcCtD
Valproic Acid—Hypertension—Epirubicin—urinary bladder cancer	3.93e-05	0.000337	CcSEcCtD
Valproic Acid—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.9e-05	0.000335	CcSEcCtD
Valproic Acid—Nervous system disorder—Methotrexate—urinary bladder cancer	3.89e-05	0.000334	CcSEcCtD
Valproic Acid—Anaemia—Doxorubicin—urinary bladder cancer	3.89e-05	0.000334	CcSEcCtD
Valproic Acid—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.88e-05	0.000333	CcSEcCtD
Valproic Acid—Chest pain—Epirubicin—urinary bladder cancer	3.87e-05	0.000332	CcSEcCtD
Valproic Acid—Myalgia—Epirubicin—urinary bladder cancer	3.87e-05	0.000332	CcSEcCtD
Valproic Acid—Arthralgia—Epirubicin—urinary bladder cancer	3.87e-05	0.000332	CcSEcCtD
Valproic Acid—Agitation—Doxorubicin—urinary bladder cancer	3.87e-05	0.000332	CcSEcCtD
Valproic Acid—Anxiety—Epirubicin—urinary bladder cancer	3.86e-05	0.000331	CcSEcCtD
Valproic Acid—Skin disorder—Methotrexate—urinary bladder cancer	3.85e-05	0.00033	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.84e-05	0.00033	CcSEcCtD
Valproic Acid—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.83e-05	0.000329	CcSEcCtD
Valproic Acid—Discomfort—Epirubicin—urinary bladder cancer	3.82e-05	0.000328	CcSEcCtD
Valproic Acid—Malaise—Doxorubicin—urinary bladder cancer	3.79e-05	0.000325	CcSEcCtD
Valproic Acid—Dry mouth—Epirubicin—urinary bladder cancer	3.79e-05	0.000325	CcSEcCtD
Valproic Acid—Vertigo—Doxorubicin—urinary bladder cancer	3.78e-05	0.000324	CcSEcCtD
Valproic Acid—Anorexia—Methotrexate—urinary bladder cancer	3.78e-05	0.000324	CcSEcCtD
Valproic Acid—Leukopenia—Doxorubicin—urinary bladder cancer	3.77e-05	0.000323	CcSEcCtD
Valproic Acid—Confusional state—Epirubicin—urinary bladder cancer	3.74e-05	0.000321	CcSEcCtD
Valproic Acid—Palpitations—Doxorubicin—urinary bladder cancer	3.72e-05	0.000319	CcSEcCtD
Valproic Acid—Oedema—Epirubicin—urinary bladder cancer	3.71e-05	0.000318	CcSEcCtD
Valproic Acid—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.71e-05	0.000318	CcSEcCtD
Valproic Acid—Hypotension—Methotrexate—urinary bladder cancer	3.71e-05	0.000318	CcSEcCtD
Valproic Acid—Infection—Epirubicin—urinary bladder cancer	3.69e-05	0.000316	CcSEcCtD
Valproic Acid—Cough—Doxorubicin—urinary bladder cancer	3.67e-05	0.000315	CcSEcCtD
Valproic Acid—Nervous system disorder—Epirubicin—urinary bladder cancer	3.64e-05	0.000312	CcSEcCtD
Valproic Acid—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.63e-05	0.000312	CcSEcCtD
Valproic Acid—Hypertension—Doxorubicin—urinary bladder cancer	3.63e-05	0.000312	CcSEcCtD
Valproic Acid—Tachycardia—Epirubicin—urinary bladder cancer	3.62e-05	0.000311	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.61e-05	0.00031	CcSEcCtD
Valproic Acid—Skin disorder—Epirubicin—urinary bladder cancer	3.6e-05	0.000309	CcSEcCtD
Valproic Acid—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.59e-05	0.000308	CcSEcCtD
Valproic Acid—Insomnia—Methotrexate—urinary bladder cancer	3.59e-05	0.000308	CcSEcCtD
Valproic Acid—Chest pain—Doxorubicin—urinary bladder cancer	3.58e-05	0.000307	CcSEcCtD
Valproic Acid—Myalgia—Doxorubicin—urinary bladder cancer	3.58e-05	0.000307	CcSEcCtD
Valproic Acid—Arthralgia—Doxorubicin—urinary bladder cancer	3.58e-05	0.000307	CcSEcCtD
Valproic Acid—Anxiety—Doxorubicin—urinary bladder cancer	3.57e-05	0.000306	CcSEcCtD
Valproic Acid—Paraesthesia—Methotrexate—urinary bladder cancer	3.56e-05	0.000305	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.56e-05	0.000305	CcSEcCtD
Valproic Acid—Discomfort—Doxorubicin—urinary bladder cancer	3.54e-05	0.000304	CcSEcCtD
Valproic Acid—Anorexia—Epirubicin—urinary bladder cancer	3.54e-05	0.000303	CcSEcCtD
Valproic Acid—Dyspnoea—Methotrexate—urinary bladder cancer	3.54e-05	0.000303	CcSEcCtD
Valproic Acid—Somnolence—Methotrexate—urinary bladder cancer	3.53e-05	0.000302	CcSEcCtD
Valproic Acid—Dry mouth—Doxorubicin—urinary bladder cancer	3.5e-05	0.0003	CcSEcCtD
Valproic Acid—Dyspepsia—Methotrexate—urinary bladder cancer	3.49e-05	0.000299	CcSEcCtD
Valproic Acid—Hypotension—Epirubicin—urinary bladder cancer	3.47e-05	0.000297	CcSEcCtD
Valproic Acid—Confusional state—Doxorubicin—urinary bladder cancer	3.46e-05	0.000297	CcSEcCtD
Valproic Acid—Decreased appetite—Methotrexate—urinary bladder cancer	3.45e-05	0.000296	CcSEcCtD
Valproic Acid—Oedema—Doxorubicin—urinary bladder cancer	3.43e-05	0.000295	CcSEcCtD
Valproic Acid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.43e-05	0.000295	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.42e-05	0.000294	CcSEcCtD
Valproic Acid—Fatigue—Methotrexate—urinary bladder cancer	3.42e-05	0.000293	CcSEcCtD
Valproic Acid—Infection—Doxorubicin—urinary bladder cancer	3.41e-05	0.000293	CcSEcCtD
Valproic Acid—Pain—Methotrexate—urinary bladder cancer	3.39e-05	0.000291	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.38e-05	0.00029	CcSEcCtD
Valproic Acid—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.37e-05	0.000289	CcSEcCtD
Valproic Acid—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.36e-05	0.000288	CcSEcCtD
Valproic Acid—Insomnia—Epirubicin—urinary bladder cancer	3.36e-05	0.000288	CcSEcCtD
Valproic Acid—Tachycardia—Doxorubicin—urinary bladder cancer	3.35e-05	0.000287	CcSEcCtD
Valproic Acid—Skin disorder—Doxorubicin—urinary bladder cancer	3.34e-05	0.000286	CcSEcCtD
Valproic Acid—Paraesthesia—Epirubicin—urinary bladder cancer	3.33e-05	0.000286	CcSEcCtD
Valproic Acid—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.32e-05	0.000285	CcSEcCtD
Valproic Acid—Dyspnoea—Epirubicin—urinary bladder cancer	3.31e-05	0.000284	CcSEcCtD
Valproic Acid—Somnolence—Epirubicin—urinary bladder cancer	3.3e-05	0.000283	CcSEcCtD
Valproic Acid—Anorexia—Doxorubicin—urinary bladder cancer	3.27e-05	0.000281	CcSEcCtD
Valproic Acid—Feeling abnormal—Methotrexate—urinary bladder cancer	3.27e-05	0.00028	CcSEcCtD
Valproic Acid—Dyspepsia—Epirubicin—urinary bladder cancer	3.27e-05	0.00028	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.24e-05	0.000278	CcSEcCtD
Valproic Acid—Decreased appetite—Epirubicin—urinary bladder cancer	3.23e-05	0.000277	CcSEcCtD
Valproic Acid—Hypotension—Doxorubicin—urinary bladder cancer	3.21e-05	0.000275	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.2e-05	0.000275	CcSEcCtD
Valproic Acid—Fatigue—Epirubicin—urinary bladder cancer	3.2e-05	0.000274	CcSEcCtD
Valproic Acid—Pain—Epirubicin—urinary bladder cancer	3.17e-05	0.000272	CcSEcCtD
Valproic Acid—Constipation—Epirubicin—urinary bladder cancer	3.17e-05	0.000272	CcSEcCtD
Valproic Acid—Urticaria—Methotrexate—urinary bladder cancer	3.15e-05	0.00027	CcSEcCtD
Valproic Acid—Body temperature increased—Methotrexate—urinary bladder cancer	3.13e-05	0.000269	CcSEcCtD
Valproic Acid—Abdominal pain—Methotrexate—urinary bladder cancer	3.13e-05	0.000269	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.13e-05	0.000268	CcSEcCtD
Valproic Acid—Insomnia—Doxorubicin—urinary bladder cancer	3.11e-05	0.000266	CcSEcCtD
Valproic Acid—Paraesthesia—Doxorubicin—urinary bladder cancer	3.08e-05	0.000264	CcSEcCtD
Valproic Acid—Dyspnoea—Doxorubicin—urinary bladder cancer	3.06e-05	0.000263	CcSEcCtD
Valproic Acid—Feeling abnormal—Epirubicin—urinary bladder cancer	3.06e-05	0.000262	CcSEcCtD
Valproic Acid—Somnolence—Doxorubicin—urinary bladder cancer	3.05e-05	0.000262	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.03e-05	0.00026	CcSEcCtD
Valproic Acid—Dyspepsia—Doxorubicin—urinary bladder cancer	3.02e-05	0.000259	CcSEcCtD
Valproic Acid—Decreased appetite—Doxorubicin—urinary bladder cancer	2.98e-05	0.000256	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.96e-05	0.000254	CcSEcCtD
Valproic Acid—Fatigue—Doxorubicin—urinary bladder cancer	2.96e-05	0.000254	CcSEcCtD
Valproic Acid—Urticaria—Epirubicin—urinary bladder cancer	2.95e-05	0.000253	CcSEcCtD
Valproic Acid—Constipation—Doxorubicin—urinary bladder cancer	2.94e-05	0.000252	CcSEcCtD
Valproic Acid—Pain—Doxorubicin—urinary bladder cancer	2.94e-05	0.000252	CcSEcCtD
Valproic Acid—Body temperature increased—Epirubicin—urinary bladder cancer	2.93e-05	0.000252	CcSEcCtD
Valproic Acid—Abdominal pain—Epirubicin—urinary bladder cancer	2.93e-05	0.000252	CcSEcCtD
Valproic Acid—Hypersensitivity—Methotrexate—urinary bladder cancer	2.92e-05	0.000251	CcSEcCtD
Valproic Acid—Asthenia—Methotrexate—urinary bladder cancer	2.85e-05	0.000244	CcSEcCtD
Valproic Acid—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.83e-05	0.000243	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.81e-05	0.000241	CcSEcCtD
Valproic Acid—Pruritus—Methotrexate—urinary bladder cancer	2.81e-05	0.000241	CcSEcCtD
Valproic Acid—Hypersensitivity—Epirubicin—urinary bladder cancer	2.73e-05	0.000235	CcSEcCtD
Valproic Acid—Urticaria—Doxorubicin—urinary bladder cancer	2.73e-05	0.000234	CcSEcCtD
Valproic Acid—Abdominal pain—Doxorubicin—urinary bladder cancer	2.71e-05	0.000233	CcSEcCtD
Valproic Acid—Body temperature increased—Doxorubicin—urinary bladder cancer	2.71e-05	0.000233	CcSEcCtD
Valproic Acid—Diarrhoea—Methotrexate—urinary bladder cancer	2.71e-05	0.000233	CcSEcCtD
Valproic Acid—Asthenia—Epirubicin—urinary bladder cancer	2.66e-05	0.000228	CcSEcCtD
Valproic Acid—Pruritus—Epirubicin—urinary bladder cancer	2.63e-05	0.000225	CcSEcCtD
Valproic Acid—Dizziness—Methotrexate—urinary bladder cancer	2.62e-05	0.000225	CcSEcCtD
Valproic Acid—Diarrhoea—Epirubicin—urinary bladder cancer	2.54e-05	0.000218	CcSEcCtD
Valproic Acid—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.53e-05	0.000217	CcSEcCtD
Valproic Acid—Vomiting—Methotrexate—urinary bladder cancer	2.52e-05	0.000216	CcSEcCtD
Valproic Acid—Rash—Methotrexate—urinary bladder cancer	2.5e-05	0.000214	CcSEcCtD
Valproic Acid—Dermatitis—Methotrexate—urinary bladder cancer	2.5e-05	0.000214	CcSEcCtD
Valproic Acid—Headache—Methotrexate—urinary bladder cancer	2.48e-05	0.000213	CcSEcCtD
Valproic Acid—Asthenia—Doxorubicin—urinary bladder cancer	2.46e-05	0.000211	CcSEcCtD
Valproic Acid—Dizziness—Epirubicin—urinary bladder cancer	2.45e-05	0.00021	CcSEcCtD
Valproic Acid—Pruritus—Doxorubicin—urinary bladder cancer	2.43e-05	0.000208	CcSEcCtD
Valproic Acid—Vomiting—Epirubicin—urinary bladder cancer	2.36e-05	0.000202	CcSEcCtD
Valproic Acid—Nausea—Methotrexate—urinary bladder cancer	2.36e-05	0.000202	CcSEcCtD
Valproic Acid—Diarrhoea—Doxorubicin—urinary bladder cancer	2.35e-05	0.000202	CcSEcCtD
Valproic Acid—Rash—Epirubicin—urinary bladder cancer	2.34e-05	0.000201	CcSEcCtD
Valproic Acid—Dermatitis—Epirubicin—urinary bladder cancer	2.34e-05	0.000201	CcSEcCtD
Valproic Acid—Headache—Epirubicin—urinary bladder cancer	2.32e-05	0.000199	CcSEcCtD
Valproic Acid—Dizziness—Doxorubicin—urinary bladder cancer	2.27e-05	0.000195	CcSEcCtD
Valproic Acid—Nausea—Epirubicin—urinary bladder cancer	2.2e-05	0.000189	CcSEcCtD
Valproic Acid—Vomiting—Doxorubicin—urinary bladder cancer	2.18e-05	0.000187	CcSEcCtD
Valproic Acid—Rash—Doxorubicin—urinary bladder cancer	2.17e-05	0.000186	CcSEcCtD
Valproic Acid—Dermatitis—Doxorubicin—urinary bladder cancer	2.16e-05	0.000186	CcSEcCtD
Valproic Acid—Headache—Doxorubicin—urinary bladder cancer	2.15e-05	0.000185	CcSEcCtD
Valproic Acid—Nausea—Doxorubicin—urinary bladder cancer	2.04e-05	0.000175	CcSEcCtD
Valproic Acid—HDAC2—Signaling Pathways—TERT—urinary bladder cancer	5.13e-06	4.23e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.12e-06	4.23e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.12e-06	4.23e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PPARG—urinary bladder cancer	5.09e-06	4.2e-05	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—KRAS—urinary bladder cancer	5.07e-06	4.18e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.06e-06	4.18e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	5.03e-06	4.15e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—TYMS—urinary bladder cancer	4.96e-06	4.09e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.96e-06	4.09e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—ENO2—urinary bladder cancer	4.94e-06	4.07e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	4.94e-06	4.07e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—NQO1—urinary bladder cancer	4.93e-06	4.07e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	4.91e-06	4.05e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	4.91e-06	4.05e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	4.89e-06	4.03e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.83e-06	3.98e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.83e-06	3.98e-05	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—PTGS2—urinary bladder cancer	4.81e-06	3.97e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—ERBB2—urinary bladder cancer	4.79e-06	3.95e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	4.79e-06	3.95e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.72e-06	3.89e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—FGFR3—urinary bladder cancer	4.71e-06	3.88e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.71e-06	3.88e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—GPX1—urinary bladder cancer	4.7e-06	3.88e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—PTGS2—urinary bladder cancer	4.69e-06	3.87e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.69e-06	3.87e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.68e-06	3.86e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.67e-06	3.85e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	4.61e-06	3.8e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—ESR1—urinary bladder cancer	4.57e-06	3.77e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.52e-06	3.73e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.51e-06	3.72e-05	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—TP53—urinary bladder cancer	4.5e-06	3.72e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PPARG—urinary bladder cancer	4.45e-06	3.67e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.41e-06	3.64e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—GSTP1—urinary bladder cancer	4.35e-06	3.59e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	4.34e-06	3.58e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PPARG—urinary bladder cancer	4.33e-06	3.57e-05	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—HRAS—urinary bladder cancer	4.31e-06	3.55e-05	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—PTGS2—urinary bladder cancer	4.29e-06	3.54e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	4.27e-06	3.52e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.26e-06	3.51e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.22e-06	3.48e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.21e-06	3.47e-05	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—PTEN—urinary bladder cancer	4.2e-06	3.46e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—ENO2—urinary bladder cancer	4.18e-06	3.45e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	4.18e-06	3.45e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.16e-06	3.43e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	4.16e-06	3.43e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	4.11e-06	3.39e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—CDKN1A—urinary bladder cancer	4.1e-06	3.38e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—PTEN—urinary bladder cancer	4.09e-06	3.37e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	4.06e-06	3.35e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—TYMS—urinary bladder cancer	4.05e-06	3.34e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.03e-06	3.33e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—RRM2—urinary bladder cancer	4.03e-06	3.32e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—TYMP—urinary bladder cancer	4.02e-06	3.32e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CREBBP—urinary bladder cancer	4.01e-06	3.31e-05	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—EP300—urinary bladder cancer	4e-06	3.3e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	4e-06	3.3e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—NCOR1—urinary bladder cancer	4e-06	3.3e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—GSTM1—urinary bladder cancer	4e-06	3.3e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.99e-06	3.29e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.98e-06	3.29e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—NQO1—urinary bladder cancer	3.98e-06	3.28e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—IGF1—urinary bladder cancer	3.96e-06	3.27e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—EP300—urinary bladder cancer	3.9e-06	3.22e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.89e-06	3.21e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.88e-06	3.2e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.86e-06	3.19e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—GPX1—urinary bladder cancer	3.83e-06	3.16e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—TYMS—urinary bladder cancer	3.83e-06	3.16e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—SRC—urinary bladder cancer	3.79e-06	3.13e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	3.78e-06	3.12e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	3.78e-06	3.12e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—ERCC2—urinary bladder cancer	3.76e-06	3.1e-05	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—PTEN—urinary bladder cancer	3.74e-06	3.09e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.73e-06	3.08e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.73e-06	3.08e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.71e-06	3.06e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.67e-06	3.03e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Gene Expression—MYC—urinary bladder cancer	3.66e-06	3.02e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.64e-06	3e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—RHOA—urinary bladder cancer	3.63e-06	2.99e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—GPX1—urinary bladder cancer	3.62e-06	2.99e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.62e-06	2.99e-05	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—EP300—urinary bladder cancer	3.57e-06	2.94e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.56e-06	2.94e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	3.56e-06	2.93e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—MTHFR—urinary bladder cancer	3.53e-06	2.92e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PPARG—urinary bladder cancer	3.52e-06	2.9e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	3.5e-06	2.89e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PTEN—urinary bladder cancer	3.49e-06	2.88e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	3.4e-06	2.81e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.4e-06	2.81e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.4e-06	2.81e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—MYC—urinary bladder cancer	3.4e-06	2.8e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.38e-06	2.79e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	3.38e-06	2.79e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.37e-06	2.78e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—ERBB2—urinary bladder cancer	3.36e-06	2.77e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	3.34e-06	2.76e-05	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—EP300—urinary bladder cancer	3.33e-06	2.75e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—EGFR—urinary bladder cancer	3.32e-06	2.74e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	3.32e-06	2.74e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.3e-06	2.72e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.27e-06	2.7e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.25e-06	2.68e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.25e-06	2.68e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CXCL8—urinary bladder cancer	3.18e-06	2.63e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.14e-06	2.59e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—KRAS—urinary bladder cancer	3.14e-06	2.59e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.1e-06	2.56e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—TYMS—urinary bladder cancer	3.09e-06	2.55e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PTEN—urinary bladder cancer	3.05e-06	2.52e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	3.05e-06	2.52e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	3.05e-06	2.52e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—IL2—urinary bladder cancer	3.04e-06	2.51e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—TYMS—urinary bladder cancer	3.02e-06	2.49e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.01e-06	2.48e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.98e-06	2.46e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.98e-06	2.46e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PTEN—urinary bladder cancer	2.97e-06	2.45e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CCND1—urinary bladder cancer	2.97e-06	2.45e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GPX1—urinary bladder cancer	2.92e-06	2.41e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.92e-06	2.41e-05	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—EP300—urinary bladder cancer	2.91e-06	2.4e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.91e-06	2.4e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.91e-06	2.4e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.89e-06	2.38e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MMP9—urinary bladder cancer	2.88e-06	2.37e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.87e-06	2.37e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	2.87e-06	2.37e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PPARG—urinary bladder cancer	2.87e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PTEN—urinary bladder cancer	2.86e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.86e-06	2.36e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.85e-06	2.35e-05	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—EP300—urinary bladder cancer	2.83e-06	2.33e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.82e-06	2.33e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.81e-06	2.32e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.81e-06	2.32e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.8e-06	2.31e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.78e-06	2.29e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	2.77e-06	2.28e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—CREBBP—urinary bladder cancer	2.75e-06	2.27e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.74e-06	2.26e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—EP300—urinary bladder cancer	2.73e-06	2.25e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.72e-06	2.24e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PPARG—urinary bladder cancer	2.71e-06	2.24e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	2.7e-06	2.22e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—HRAS—urinary bladder cancer	2.67e-06	2.2e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.66e-06	2.2e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—SRC—urinary bladder cancer	2.65e-06	2.19e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.64e-06	2.17e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.61e-06	2.16e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	2.6e-06	2.15e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.58e-06	2.13e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.58e-06	2.13e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.55e-06	2.1e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.51e-06	2.07e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.47e-06	2.04e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.43e-06	2e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.43e-06	2e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.42e-06	2e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PTEN—urinary bladder cancer	2.41e-06	1.99e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MYC—urinary bladder cancer	2.38e-06	1.96e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.34e-06	1.93e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.33e-06	1.92e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—EGFR—urinary bladder cancer	2.33e-06	1.92e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.32e-06	1.91e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.31e-06	1.9e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.31e-06	1.9e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—EP300—urinary bladder cancer	2.3e-06	1.9e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.29e-06	1.89e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.28e-06	1.88e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.27e-06	1.88e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PTGS2—urinary bladder cancer	2.25e-06	1.86e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.24e-06	1.85e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.24e-06	1.85e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.21e-06	1.83e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.21e-06	1.82e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—KRAS—urinary bladder cancer	2.2e-06	1.81e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PPARG—urinary bladder cancer	2.19e-06	1.8e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.18e-06	1.8e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.17e-06	1.79e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.14e-06	1.76e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	2.13e-06	1.76e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.13e-06	1.75e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.1e-06	1.73e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.1e-06	1.73e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	2.1e-06	1.73e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.05e-06	1.69e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.04e-06	1.68e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.01e-06	1.66e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.98e-06	1.64e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.98e-06	1.63e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.97e-06	1.62e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.95e-06	1.61e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TP53—urinary bladder cancer	1.95e-06	1.61e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.89e-06	1.56e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—EP300—urinary bladder cancer	1.87e-06	1.55e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—HRAS—urinary bladder cancer	1.87e-06	1.54e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PTEN—urinary bladder cancer	1.86e-06	1.53e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.86e-06	1.53e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.85e-06	1.53e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.82e-06	1.5e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.81e-06	1.49e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.8e-06	1.48e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.8e-06	1.48e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.78e-06	1.47e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—EP300—urinary bladder cancer	1.77e-06	1.46e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.72e-06	1.42e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.72e-06	1.42e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.69e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.68e-06	1.39e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.65e-06	1.36e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.59e-06	1.31e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.59e-06	1.31e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.51e-06	1.24e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.51e-06	1.24e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.5e-06	1.24e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.47e-06	1.21e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.46e-06	1.2e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.45e-06	1.19e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.43e-06	1.18e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.4e-06	1.16e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.4e-06	1.15e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.33e-06	1.1e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.3e-06	1.08e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.3e-06	1.07e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.29e-06	1.06e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.27e-06	1.05e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.24e-06	1.02e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.23e-06	1.01e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.21e-06	9.99e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.19e-06	9.78e-06	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.13e-06	9.35e-06	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.08e-06	8.92e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.03e-06	8.53e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.01e-06	8.35e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.94e-07	8.2e-06	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.86e-07	8.13e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.54e-07	7.87e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.83e-07	7.29e-06	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—EP300—urinary bladder cancer	8.42e-07	6.95e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.82e-07	6.45e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.82e-07	5.62e-06	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.5e-07	5.36e-06	CbGpPWpGaD
